These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 9314093

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of bisoprolol and verapamil in hypertension: influence on left ventricular mass and function--a pilot study.
    Gosse P, Gressin V, Clerson P, Lemetayer P, Clémenty J.
    Therapie; 1999; 54(2):217-22. PubMed ID: 10394257
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
    Díez J, Laviades C.
    J Hypertens Suppl; 1994 Jul; 12(4):S31-6. PubMed ID: 7965272
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Evaluation of regression of left ventricular hypertrophy after antihypertensive therapy. Comparative echo-Doppler study of ace inhibitors and calcium antagonists].
    Totteri A, Scopelliti G, Campanella G, Bertini M, Castro R, Pintus G, Jommi E.
    Minerva Cardioangiol; 1993 Jun; 41(6):231-7. PubMed ID: 8361609
    [Abstract] [Full Text] [Related]

  • 7. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure.
    Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG.
    Nephrol Dial Transplant; 1997 May; 12(5):945-51. PubMed ID: 9175047
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Absence of detectable regression of human hypertensive left ventricular hypertrophy following drug treatment for 1 year.
    Laufer E, Reid C, Qi XL, Jennings GL.
    Clin Exp Pharmacol Physiol; 1998 May; 25(3-4):208-15. PubMed ID: 9590570
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients.
    Scognamiglio R, Nosadini R, Marin M, Nisti S, Fasoli G, Palisi M, Frigato F, Virgili F, Carraro A, Crepaldi G.
    Diabetes Care; 1997 Aug; 20(8):1290-2. PubMed ID: 9250456
    [Abstract] [Full Text] [Related]

  • 15. Antihypertensive effects of verapamil, captopril and their combination at rest and during dynamic exercise.
    Di Somma S, Petitto M, Liguori V, Carotenuto A, Paulucci A, De Divitiis O.
    Arzneimittelforschung; 1992 Feb; 42(2):103-7. PubMed ID: 1610414
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy.
    Machnig T, Henneke KH, Engels G, Pongratz G, Schmalzl M, Gellert J, Bachmann K.
    Cardiology; 1994 Feb; 85(2):101-10. PubMed ID: 7954561
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Pharmacologic regression of cardiac and vascular structural changes in the hypertensive patient. A question that goes beyond the exclusive medical bias].
    Antonio Francischetti E, Genelhu Fagundes V, Francischetti A.
    Arq Bras Cardiol; 1995 Dec; 65(6):555-63. PubMed ID: 8731314
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.